Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)
Daniele Cretella(Institute of Molecular Biology and Pathology)
DSpaceUnipr (University of Parma)
January 1, 2015
Cited by 0